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Objectives: Characterizing pharmacological response in Parkinson’s Disease (PD)
patients may be a challenge in early stages but gives valuable clues for diagnosis.
Neurotropic drugs may modulate Electroencephalography (EEG) microstates (MS). We
investigated EEG-MS default-mode network changes in response to dopaminergic
stimulation in PD.
Methods: Fourteen PD subjects in HY stage III or less were included, and twenty-
one healthy controls. All patients were receiving dopaminergic stimulation with levodopa
or dopaminergic agonists. Resting EEG activity was recorded before the first daily PD
medication dose and 1 h after drug intake resting EEG activity was again recorded. Time
and frequency variables for each MS were calculated.
Results: Parkinson’s disease subjects MS A duration decreases after levodopa intake,
MS B appears more often than before levodopa intake. MS E was not present, but MS
G was. There were no significant differences between control subjects and patients after
medication intake.
Conclusion: Clinical response to dopaminergic drugs in PD is characterized by clear
changes in MS profile.
Significance: This work demonstrates that there are clear EEG MS markers of PD
dopaminergic stimulation state. The characterization of the disease and its response to
dopaminergic medication may be of help for early therapeutic diagnosis.
Keywords: Parkinson’s disease, electroencephalography, microstates, levodopa, diagnosis
INTRODUCTION
Parkinson’s Disease (PD) is a neurodegenerative disease affecting up to 3% of the
population ≥ 65 years of age (Poewe et al., 2017). PD has been associated with several risk
factors common to other age related diseases and some chemicals exposure (Beitz, 2014) but its
ultimate cause is still unknown.
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In typical PD, progressive degeneration of dopaminergic
neurons in the substantia nigra is correlated with the wide known
motor symptoms of bradykinesia, rigidity, and tremor (Kalia and
Lang, 2015). However, the phenotypical profile of each patient
gives rise to the identification of several subtypes such as tremor-
dominant subtype and on the other hand bradykinesia/rigidity
dominant (Marras and Lang, 2013). Dopaminergic treatment
usually provides substantial alleviation in motor symptoms. Some
other symptoms such as gait disturbance and postural instability
do not usually have a substantial improvement (Hely et al., 2005).
There are several syndromes that share some features similar to
Parkinson’s disease, but the progression and onset of symptoms
are different. One of the main characteristics of this atypical
Parkinsonism is the lack of or incomplete response to levodopa
(Goetz et al., 2008; Stamelou and Hoeglinger, 2013).
Levodopa is actually considered the best current symptomatic
treatment for Parkinson’s Disease. One of the main obstacles for
the treatment of the disease is its pharmacodynamics, meaning
there is a low penetrance of the drug into the central nervous
system (Khor and Hsu, 2007; Britz et al., 2010; Musso et al., 2010;
Van de Ville et al., 2010; Michel and Koenig, 2017). The action
of this drug determines important changes not only in motor but
also in non-motor symptoms. The state where patients show a
marked improvement is called “ON state” and the one with no
effects is called “OFF state.” Dopamine (DA) receptor agonists
are also used to treat the symptoms of the disease since such
drugs mimic the action of dopamine, their action is achieved by
stimulation of pre-synaptic (auto receptors) and post-synaptic
DA receptors (Radad et al., 2005). Levodopa equivalent dose
(LED) can be calculated from dopamine receptor agonist doses
so the total daily levodopa administration can be estimated
(Tomlinson et al., 2010).
Dopaminergic stimulation is surely alleviating typical PD
symptoms in most patients, but the degree of its effects shows
major inter-individual differences. These differences in levodopa
motor response are evident even between same disease-severity-
stage patients (Goetz et al., 2000). Every patient has their own
needs of medication to reach their “ON state” and this varies
according to the disease progression (Nyholm et al., 2012) and
degree of denervation (Kostrzewa et al., 2005).
The clinical diagnosis of PD is currently based on clinical
symptoms and other support criteria such as response to
medication. This clinical diagnosis is very difficult, especially in
early stages of the disease when there are no remarkable motor
features.
Identification of neurophysiological variables with diagnostic
value in early-stage PD would raise the chances of improving
diagnostic certainty (Valls-Solé and Valldeoriola, 2002).
Electroencephalography (EEG) is a well-known technique
used to record the electrical field produced by the electrical
activity in the brain. This technique is characterized by a
high temporal resolution and high test–retest reliability (Lopes
da Silva, 1991). It has been published that quantifying EEG
rhythms and their variations could be the source of biomarker
for several neuropsychiatric disorders, such as schizophrenia,
major depressive disorder, or even neurodegenerative diseases as
Alzheimer’s disease (Gandal et al., 2012; Han et al., 2013).
Electroencephalography data can be analyzed according to
momentary states of the topographical brain activation, called
microstates (MS). “Microstate analysis is a method in which
states are defined by topographies of electrical potentials on a
set of multichannel electrodes that remain stable for 80–120 ms
before rapidly moving to a different microstate” (Khanna et al.,
2015). Unlike other EEG processing techniques, in microstates,
the simultaneous analysis of the signals from all the electrodes
is used to create a global representation of a functional state. In
fact, many studies have shown that time series of EEG microstates
vary through behavioral states (Stevens and Kircher, 1998;
Lehmann et al., 2010), personality types (Schlegel et al., 2012) and
neuropsychiatric disorders (Dierks et al., 1997; Lehmann et al.,
2005; Kikuchi et al., 2011; Khanna et al., 2015). Consequently,
changes in the duration or frequency of appearance of specific
microstates can be considered as biomarkers for different
neurological and neuropsychiatric conditions.
Interestingly, several studies that have examined resting-state
EEG report the same four archetypal microstates that explain
most of the global topographic variance (Koenig et al., 2002;
Khanna et al., 2015). The four canonical EEG microstates (A, B,
C, D) seem to represent the neurophysiological correlates of four
known Resting State Networks identified by fMRI, suggesting
that Resting State Networks of fMRI may be the same ones that
give rise to microstates (Michel and Koenig, 2017). The dynamics
of these networks may imply various brain functions, and their
alteration can be associated with the pathophysiology of several
neurological and neuropsychiatric diseases (Khanna et al., 2015).
When the microstate time series is convolved with the resting-
state fMRI BOLD signal, each microstate map correlates with the
activity of particular RSNs (Britz et al., 2010; Musso et al., 2010;
Yuan et al., 2016). Britz et al. (2010) showed that microstate A is
associated with the phonological processing network, B with the
visual network, C with the salience network, and D related to the
attentional network.
There is evidence that neurotropic drugs may modulate EEG
microstates (Kikuchi et al., 2007, 2011; Yoshimura et al., 2007),
but there are no studies showing EEG microstate changes in
response to the administration of levodopa or dopaminergic
agonist drugs in typical PD patients.
The aim of the study presented in this paper is to identify
EEG microstate changes that characterize levodopa response. The
data obtained from this study can be used to support typical PD
diagnosis in difficult clinical scenarios where a therapeutic trial
of levodopa is not feasible or not well tolerated by the patient
because of the gastric effects of its administration.
MATERIALS AND METHODS
Participants
The protocol was approved by the CEIC Fuenlabrada Hospital,
Madrid, Spain. All subjects gave written informed consent in
accordance with the Declaration of Helsinki.
Fourteen patients were included in the study after signing
informed consent forms (4 female: mean age 66.25 ± 12.9,
range 52–80 and 10 male: mean age 66.9 ± 7.41, range 50–76).
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All the patients had been diagnosed with Parkinson’s Disease
according to London Brain Bank criteria (mean time from onset
7.29 ± 2.33 years, range 4–13), with Hoehn and Yahr scale 2 ± 0.8
(range 1–3), and were taking levodopa or dopaminergic agonists
(mean daily amount 324.28 ± 232.77 levodopa milligrams
equivalent dose (LED), range 100–733) in stable dosing regimen
for at least 90 days with a clear ON effect (good clinical effect).
There was not head tremor in any of the patients. Table 1
shows a description of included patients. In addition, twenty-one
healthy subjects were recruited as control participants (6 female:
mean age 67.4 ± 10.21, range 50–77 and 15 male: mean age
69.6 ± 10.14, range 50–93).
Intervention
Participants were asked to come to the hospital early in the
morning without their corresponding daily levodopa or agonist
intake (at least 8 h after the last levodopa or dopamine agonist
dose). Resting EEG activity was recorded over 2 min by 64
electrodes placed according to the 10–20 system as depicted in
Figure 1. They were comfortably seated with their hands on
their laps, relaxed jaw and eyes open, looking at a white wall.
Immediately afterward, the EEG electrodes were removed, and
they took their daily Levodopa or agonist dose with a glass of
water, 30 min before they had a light breakfast and were given
free time. The resting EEG activity was analogously recorded 1 h
after the levodopa intake, once the patient had asserted they were
in their usual ON state.
Materials
An actiCHamp amplifier (Brain Vision LLC, NC, United States)
was used to amplify and digitize the EEG data at a sampling
frequency of 512 Hz. The EEG data were stored in a PC
running Windows 7 (Microsoft Corporation, Washington, DC,
United States). EEG activity was recorded from 64 positions with
active Ag/AgCl scalp electrodes (actiCAP electrodes, Brain Vision
LLC, NC, United States). The ground and reference electrodes
were placed on AFz and on FCz, respectively (see Figure 1).
Electroencephalography acquisition was carried out by
NeuroRT Studio software (Mensia Technologies SA, Paris,
France). The EEG signal processing procedure was performed
using MATLAB functions (MathWorks Inc., Natick MA,
United States), specifically the EEGLab toolbox (Delorme and
Makeig, 2004). EEG microstates were extracted and characterized
by LORETA-KEY v20170220 software (the Key Institute for
Brain-Mind Research, Zurich, Switzerland). Statistical analyses
were performed by SPSS for Windows, version 23.0 (IBM Inc.,
Chicago, IL, United States).
EEG Processing and Outcome
Measurements
The continuous EEG signal for each channel was artifact-
corrected by the Artifact Subspace Reconstruction algorithm
(Mullen et al., 2013), disabling all parameters except the high-pass
filter band width (0.25–0.75) and burst repairing (kurtosis > 5).
The signal was then band-pass filtered between 2 and 31 Hz
with a Finite Impulse Response (FIR) filter (order 846). Finally,
a common average reference (CAR) spatial filter was applied.
The processed EEG was the input to an EEG microstate
detection and characterization algorithm (Pascual-Marqui et al.,
2014). The algorithm requires an initial interval for the number
of microstates searched. This interval was set to 4–10. The
algorithm was run independently for PD PRE, PD POST and
CONTROL conditions. Mean microstate topographies in each
condition were manually assigned to canonical microstates
reported in previous studies. The assignment was individually
performed by three judges (among the authors) by visual analysis.














1 Male 73 Right 8 1 14 1002,3 50 150
2 Male 67 Left 6 1 8 1002 0 100
3 Female 59 Left 6 1 10 4202,4 50 470
4 Female 74 Left 9 3 12 4002,5 250 650
5 Male 71 Left 8 2.5 15 0 100 100
6 Female 80 Right 9 3 14 5202,4,7 200 720
7 Male 76 Left 13 3 30 2203,5,6 0 220
8 Male 50 Left 5 2 24 1002 0 100
9 Male 68 Left 6 2 11 3101,2 0 310
10 Male 69 Left 6 1 22 1051 250 355
11 Male 69 Left 8 2 16 2051,2,3 100 305
12 Female 52 Right 4 2 12 1002 67 167
13 Male 59 Right 9 3 11 5501,3,5,6 283 833





















∗UPDRS, Unified Parkinson’s Disease Rating Scale. 1Pramipexole, 2Rasagiline, 3Benserazide, 4Ropirinole, 5Rotigotine, 6Safinamide, 7Amantadine.
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FIGURE 1 | Electroencephalography (EEG) electrode placement for the study.
This procedure avoids the likely mislabeling introduced by the
common topography correlation analysis in the presence of
irregular topographies and more than four microstates (Custo
et al., 2017). Labels agreed by two or more judges were assigned
(all mean microstate topographies labels were agreed by two
judges at least). From this algorithm, the microstates accounting
for most of the variance were selected. For each microstate, the
percentage of the total time in the microstate (coverage), the
percentage of times entered in the microstate (frequency), the
number of times entered in the microstate (occurrence) and the
average duration of the microstate are calculated. In addition, the
frequency and probability of change from each microstate to each
other one are also calculated, giving a total of 6 features for each
microstate.
Statistical Analysis
The microstate features mentioned above are compared between
the pre- and post-levodopa intake conditions. The difference
of averages between pre- and post-conditions for each feature
was checked by a t-test for repeated measurements with
bootstrapping (n = 1000). Differences with a significance p< 0.05
and confidence intervals (lower and upper) with the same sign
were considered as statistically significant.
RESULTS
Figure 2 shows the microstates topographies found in pre- (first
column) and post- (second column) levodopa intake conditions.
Control group (third column) is examined with no medication.
In the pre-condition (OFF state), canonical A, B and C
microstates were found with a percentage of explained variance
of 19.55, 20.34 and 18.55%, respectively. Canonical microstate D
was not identified. Microstates B and C presented altered patterns
with respect to the findings in the literature (Michel and Koenig,
2017). In the absence of levodopa intake, a microstate E was also
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FIGURE 2 | Average topographic distributions of found microstates in pre- and post-levodopa intake conditions and control condition.
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TABLE 2 | Statistically significant differences in features of Electroencephalography (EEG) microstates between pre- and post-levodopa intake in Parkinson’s patients.
N = 14 Average difference (POST-PRE) Bootstrapping simulation
SE p 95% CI
Lower Upper
Average duration A −0.00006864 0.00002078 0.009 −0.00010 −0.000031
Occurrence B 549.28571 47.85855 < 0.0001 419.67657 642.10915
Frequency B to A −680.17248 214.30544 0.033 −1026.77105 −271.71723
SE, Standard error; p, significance value; CI, Confidence interval.
TABLE 3 | Statistically significant differences in features of EEG microstates between post-levodopa intake of Parkinson’s patients and control participants.
N = 21 Average difference (Control-PD POST) Bootstrapping simulation (n = 1000)
SE p 95% CI
Lower Upper
% EV D −5.198024 1.425808 0.004 −8.223715 −2.748249
Coverage D −12.136262 2.076990 0.001 −16.321933 −8.071208
Average duration D −0.00009076 0.00003172 0.024 −0.00015279 −0.00002818
Occurrence A −86.500 33.004 0.015 −150.628 −21.874
Occurrence C −89.167 31.995 0.011 −154.717 −28.991
Occurrence D −213.238 26.329 0.001 −262.567 −161.391
Occurrence G −106.167 34.890 0.005 −171.316 −37.608
Probability A to D −0.15608055 0.025070321 0.001 −0.207682815 −0.10978173
Probability B to D −0.134840881 0.021954275 0.001 −0.175374815 −0.0919498
Probability C to D −0.174758333 0.026128700 0.001 −0.229032260 −0.1263252
Probability G to D −0.111732048 0.027221222 0.001 −0.163486738 −0.0606472
EV, Explained variance; SE, Standard error; p, significance value; CI, Confidence interval.
found, in congruence with the definition of Custo et al. (2017),
with an explained variance of 19.58%.
After levodopa intake (ON state), the four canonical
microstates A, B, C, and D were found with normal patterns
(Michel and Koenig, 2017), and explained variances of 20.12,
18.39, 20.00, and 16.67%, respectively. Microstate E was no
longer present after levodopa intake. However, the microstate G,
according to Custo et al. (2017), was found with an explained
variance of 15.39%. Control participants presented the same
latter microstates (Figure 2, third column), with A, B, C, D, and
G percentages of global explained variance of 20.85, 22.51, 17.49,
7.06, and 12.42%, respectively.
Given that the two patient conditions only share three
microstates (A, B, and C), Table 2 presents the statistically
significant differences in the features of those three microstates
between the OFF and ON states. The remaining features not
present in Table 2 did not show significant differences.
According to the results in Table 2, the microstate A shows a
decreased duration after levodopa intake. Moreover, microstate
B appears more often than before levodopa intake. Finally, the
frequency of transition from microstate B to A got decreased with
levodopa.
Table 3 presents the statistically significant differences in
microstate features between control participants and patients
after levodopa intake. No significant differences in microstate
features were found between control participants and patients
before levodopa intake. All microstate types except B occurred
more often in post-levodopa patients than in control participants.
This difference is especially high for microstate D, which
also presented a higher explained variance and coverage. The
probability of shifting from all microstates to D was also higher in
post-levodopa patients, as is justified by the mentioned increased
occurrence of the latter.
DISCUSSION
The fact that control subjects and PD patients after taking
levodopa show the same microstate types is supported by the fact
that levodopa is known to restore altered motor and non-motor
functions in PD patients.
A higher duration of microstate A has been related to clinical
variables such as disability and cognitive fatigue in patients with
multiple sclerosis (Gschwind et al., 2016), and could be related
to the cognitive fatigue presented by patients with PD. Such
fatigue decreases with dopaminergic stimulation, and therefore
it can lead to a decrease in the duration of microstate A,
as observed in the results obtained in our study. As we said
earlier that Britz et al. (2010) showed that microstate B is
associated with the visual network, then the observed increase
in the number of times microstate B is present after levodopa
or dopaminergic agonist intake might be explained by a lower
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fatigability in visual monitoring and a better functioning of PD
patients thanks to the medication (Lou, 2009, 2015), reflecting the
tendency of visual network generators to be active in the absence
of cognitive fatigue (Milz et al., 2017). Cognitive fatigability
is most likely associated with neurotransmitter (dopaminergic,
cholinergic, and noradrenergic) abnormalities in PD. Levodopa
may be effective in treating fatigue and fatigability (Lou, 2015).
The decrease of frequency of transition from microstate B to A
with dopaminergic stimulation does not seem to be related to any
known clinical or behavioral condition. Therefore, more research
is needed on the importance and functional correlation of the
transition of microstates.
There are no differences in characteristics for the microstates
shared by patients before medication intake and the controls.
However, after levodopa intake there are differences, mainly in
the microstate D. There are studies that demonstrate reduced
duration (Kikuchi et al., 2007; Nishida et al., 2013) and also
a lower frequency of appearance (Lehmann et al., 2010) of
microstate D in patients with schizophrenia. Schizophrenia is
believed to have a dopaminergic deficit up to a certain point
that could explain this common finding in PD (Van Den Brink
et al., 2018). Consequently, it is to be expected that patients
diagnosed with PD have a lower frequency of appearance of
microstate D before taking the medication. Patients presented a
greater frequency and duration of microstate D after increasing
dopaminergic stimulation, as a consequence of taking the
medication. This increase is even greater than in healthy controls,
which, assuming that microstate D reflects dopaminergic activity,
could be a result of an acute increase of this activity in the brain.
Regarding topographic considerations, microstate D is mainly
due to the activation of the right inferior parietal (BA40), the
right middle and superior frontal gyri and the right insula
(BA13) (Custo et al., 2017). The right inferior parietal area
is related to executive control and vision-guided movements
(Lasaponara et al., 2018) and the insula has a direct relationship
with motor planning (Beurze et al., 2007). The right middle
and superior frontal areas seem to explain the changes related
to the improvement in attention (Angelidis et al., 2018). The
appearance of microstate D, after taking medication, is congruent
and consistent with the disappearance of certain motor and
non-motor symptoms after levodopa.
Apart from the four canonical microstates (A–D) (Custo et al.,
2017), two additional microstates (E and G) were identified. The
microstate E corresponds to the activation of the middle frontal
gyrus, the dorsal part of the anterior cingulate, the cuneus and
the thalamus. Dopamine has an inhibitory effect (D2 receptors).
Consequently, it is plausible to attribute a relative hyperactivity
in its absence to the thalamus, and that this relative hyperactivity
disappears after the intake of levodopa. Besides, according to Yoo
et al. (2015), the anterior cingulate and frontal areas correspond
to the presence of non-motor symptoms. Therefore, this justifies
the presence of microstate E in patients before dopaminergic
stimulation and its disappearance after they took levodopa (Lou,
2009, 2015). Finally, the cuneus is also related with oculomotor
control (Darby et al., 1996), which is well-known to also be
a function specifically regulated by the basal ganglia, whose
function is altered in PD (Pretegiani and Optican, 2017).
The microstate G corresponds to the activation of the
right inferior parietal lobe, extending to the superior temporal
gyrus and also the cerebellum (Khanna et al., 2015). Both
areas are closely related to motor behavior (Pirondini et al.,
2017). Therefore, the appearance of microstate G after levodopa
intake is strongly consistent with the improvement of motor
symptoms. Since the visible and clinically evaluable motor
symptoms disappear with the medication intake, this results in
the observation of the microstate G.
The present study is not without limitations. First, the
sample size is relatively small. A larger population might
have yielded more significant results. Second, the sample
population is heterogeneous in medication terms, with different
types and doses of drugs, although they are all in their
optimal ON state. Heterogeneity in medication is usual
in PD patient cohorts because such variations correspond
to the different treatment strategies that can be initiated
even in the same disease stage. Dopaminergic agonists play
a key role in actual treatment of the disease and their
diversity makes them comparable only by their conversion
to dopaminergic equivalents as we did in our study. Besides,
cognitive fatigue, related to microstates A and B, was not
assessed in this study. Cognitive fatigability and cognitive
fatigue are usually evaluated through self-reporting scales.
Given that our measures were performed in sequential OFF
and ON state (in less than 2 h), we considered that this
evaluation would have had a very important bias of motor and
emotional symptoms as product of dopaminergic deprivation.
In addition, dopaminergic therapy optimization is one of
the main management recommendations for treating fatigue
in PD (Kostić, 2016). Finally, no cognitive evaluation was
performed, specially attention changes that are highly related to
microstate D. Nevertheless, cognitive symptoms improvement,
included attention span, has been widely reported in PD patients
in response to dopaminergic treatment and can be assumed as a
well stablished effect of medication. These limitations should be
taken into consideration when interpreting the conclusions of the
study.
CONCLUSION
Electroencephalography microstate analysis can be performed by
means of an economical and minimally invasive technique with
high temporal resolution. Since the EEG microstate correlation
with RSNs has been evidenced, the results obtained from
microstate analysis have been interpreted based on the known
findings about these networks. Our work has demonstrated that
there is an alteration of EEG microstate features and occurrence
in typical PD in response to levodopa administration. These
changes correlate with known clinical effects of the substance on
such patients and are coherent with related changes in RSNs.
In spite of the differences between controls and PD patients,
the microstates found in patients after levodopa intake are closer
to controls’ microstates than before taking the medication. Thus,
the analysis performed in this study can be considered as a means
to assess the suitability of the patients’ medication dosage.
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Further, not every Parkinsonian patient has a good response
to levodopa or dopamine agonist treatment, and patients who
were non-respondent to levodopa are excluded from typical PD
diagnosis. Absence of complete clinical response to Levodopa is
common on atypical parkinsonian patients. This lack of effect
of dopaminergic stimulation is considered a red flag and implies
the exclusion for typical Parkinson’s Disease diagnosis (Postuma
et al., 2015). Considering our results, we would not expect a
microstate “normalization” in atypical PD patients in response to
dopamine administration. Consequently, the microstate analysis
can be considered of great utility to characterize the levodopa
response prior to making a diagnosis of typical vs. atypical
Parkinsonism in a non-invasive way suitable for outpatients.
Nevertheless, further studies are required to characterize EEG
microstate changes due to levodopa administration on atypical
PD patients.
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of fatigue in Parkinson’s Disease and its pragmatic management. Mov. Disord.
Clin. Pract. 3, 323–330. doi: 10.1002/mdc3.12343
Kostrzewa, R. M., Nowak, P., Kostrzewa, J. P., Kostrzewa, R. A., and Brus, R.
(2005). Peculiarities of L-DOPA treatment of Parkinson’s disease. Amino Acids
28, 157–164. doi: 10.1007/s00726-005-0162-4
Lasaponara, S., D’Onofrio, M., Pinto, P., Dragone, A., Menicagli, D., Bueti, D.,
et al. (2018). EEG correlates of preparatory orienting, contextual updating
Frontiers in Neuroscience | www.frontiersin.org 8 October 2018 | Volume 12 | Article 714
fnins-12-00714 October 11, 2018 Time: 19:20 # 9
Serrano et al. Dopamine Induced Microstate EEG Changes
and inhibition of sensory processing in left spatial neglect. J. Neurosci. 38,
3792–3808. doi: 10.1523/JNEUROSCI.2817-17.2018
Lehmann, D., Faber, P. L., Galderisi, S., Herrmann, W. M., Kinoshita, T.,
Koukkou, M., et al. (2005). EEG microstate duration and syntax in acute,
medication-naive, first-episode schizophrenia: a multi-center study. Psychiatry
Res. 138, 141–156. doi: 10.1016/j.pscychresns.2004.05.007
Lehmann, D., Pascual-Marqui, R. D., Strik, W. K., and Koenig, T. (2010). Core
networks for visual-concrete and abstract thought content: a brain electric
microstate analysis. Neuroimage 49, 1073–1079. doi: 10.1016/j.neuroimage.
2009.07.054
Lopes da Silva, F. (1991). Neural mechanisms underlying brain waves: from neural
membranes to networks. Electroencephalogr. Clin. Neurophysiol. 79, 81–93.
doi: 10.1016/0013-4694(91)90044-5
Lou, J.-S. (2009). Physical and mental fatigue in Parkinson’s Disease: epidemiology,
Pathophysiology and Treatment. Drugs Aging 26, 195–208. doi: 10.2165/
00002512-200926030-00002
Lou, J. S. (2015) Fatigue in Parkinson’s Disease and potential interventions.
Neurorehabilitation 37, 25–34.
Marras, C., and Lang, A. (2013). Parkinson’s Disease subtypes: lost in translation?
J. Neurol. Neurosurg Psychiatry 84, 409–415. doi: 10.1136/jnnp-2012-303455
Michel, C. M., and Koenig, T. (2017). EEG microstates as a tool for studying the
temporal dynamics of whole-brain neuronal networks: a review. Neuroimage
180(Pt B), 577–593. doi: 10.1016/j.neuroimage.2017.11.062
Milz, P., Pascual-Marqui, R. D., Achermann, P., Kochi, K., and Faber, P. L.
(2017). The EEG microstate topography is predominantly determined by
intracortical sources in the alpha band. Neuroimage 162, 353–361. doi: 10.1016/
j.neuroimage.2017.08.058
Mullen, T., Makeig, S., Kothe, C., Chi, Y. M., Ojeda, A., and Kerth, T. (2013). “Real-
time modeling and 3d visualization of source dynamics and connectivity using
wearable EEG,” in Proceedings of the 2013 35th Annual International Conference
of the IEEE Engineering in Medicine and Biology Society (EMBC), Victoria, VIC.
2184–2187. doi: 10.1109/EMBC.2013.6609968
Musso, F., Brinkmeyer, J., Mobascher, A., Warbrick, T., and Winterer, G.
(2010). Spontaneous brain activity and EEG microstates. a novel EEG/fMRI
analysis approach to explore resting-state networks.Neuroimage 52, 1149–1161.
doi: 10.1016/j.neuroimage.2010.01.093
Nishida, K., Morishima, Y., Yoshimura, M., Isotani, T., Irisawa, S., Jann, K., et al.
(2013). EEG microstates associated with salience and frontoparietal networks
in frontotemporal dementia, schizophrenia and Alzheimer’s Disease. Clin.
Neurophysiol. 124, 1106–1114. doi: 10.1016/j.clinph.2013.01.005
Nyholm, D., Johansson, A., Aquilonius, S.-M., Hellquist, E., Lennernäs, H., and
Askmark, H. (2012). Complexity of motor response to different doses of
duodenal levodopa infusion in parkinson disease. Clin. Neuropharmacol. 35,
6–14. doi: 10.1097/WNF.0b013e31823b1ffd
Pascual-Marqui, R. D., Lehmann, D., Faber, P., Milz, P., Kochi, K., Yoshimura, M.,
et al. (2014). The resting microstate networks (RMN): cortical distributions,
dynamics, and frequency specific information flow. arXiv [Preprint].
arXiv:1411.1949
Pirondini, E., Coscia, M., Minguillon, J., Millán, J. d. R., Van De Ville, D., and
Micera, S. (2017). EEG topographies provide subject-specific correlates of
motor control. Sci. Rep. 7:13229. doi: 10.1038/s41598-017-13482-1
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J.,
et al. (2017). Parkinson Disease. Nat. Rev. Dis. Primers 3:17013. doi: 10.1038/
nrdp.2017.13
Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., et al.
(2015). MDS clinical diagnostic criteria for Parkinson’s Disease. Mov. Disord.
30, 1591–1601. doi: 10.1002/mds.26424
Pretegiani, E., and Optican, L. M. (2017). Eye movements in Parkinson’s Disease
and inherited parkinsonian syndromes. Front. Neurol. 8:592. doi: 10.3389/
fneur.2017.00592
Radad, K., Gille, G., and Rausch, W. D. (2005). Short review on dopamine agonists:
insight into clinical and research studies relevant to Parkinson’s Disease.
Pharmacol. Rep. 57, 701–712.
Schlegel, F., Lehmann, D., Faber, P. L., Milz, P., and Gianotti, L. R. (2012). EEG
microstates during resting represent personality differences. Brain Topogr. 25,
20–26. doi: 10.1007/s10548-011-0189-7
Stamelou, M., and Hoeglinger, G. U. (2013). Atypical parkinsonism: an update.
Curr. Opin. Neurol. 26, 401–405. doi: 10.1097/WCO.0b013e3283632da6
Stevens, A., and Kircher, T. (1998). Cognitive decline unlike normal aging
is associated with alterations of EEG temporo-spatial characteristics.
Eur. Arch. Psychiatry Clin. Neurosci. 248, 259–266. doi: 10.1007/s0040600
50047
Tomlinson, C. L., Stowe, R., Patel, S., Rick, C., Gray, R., Clarke, C. E., et al.
(2010). Systematic review of levodopa dose equivalency reporting in Parkinson’s
Disease. Mov. Disord. 25, 2649–2653. doi: 10.1002/mds.23429
Valls-Solé, J., and Valldeoriola, F. (2002). Neurophysiological correlate of clinical
signs in Parkinson’s Disease. Clin. Neurophysiol. 113, 792–805. doi: 10.1016/
S1388-2457(02)00080-9
Van de Ville, D., Britz, J., and Michel, C. M. (2010). EEG microstate sequences in
healthy humans at rest reveal scale-free dynamics. Proc. Natl. Acad. Sci. U.S.A.
107, 18179–18184. doi: 10.1073/pnas.1007841107
Van Den Brink, W. J., Palic, S., Köhler, I., and de Lange, E. C. M. (2018). Access to
the CNS: biomarker strategies for dopaminergic treatments. Pharm. Res. 35:64.
doi: 10.1007/s11095-017-2333-x
Yoo, K., Chung, S. J., Kim, H. S., Choung, O. H., Lee, Y. B., Kim, M. J., et al. (2015).
Neural substrates of motor and non-motor symptoms in Parkinson’s Disease:
a resting FMRI study. PLoS One 10:e0125455. doi: 10.1371/journal.pone.012
5455
Yoshimura, M., Koenig, T., Irisawa, S., Isotani, T., Yamada, K., Kikuchi, M.,
et al. (2007). A pharmaco-EEG study on antipsychotic drugs in healthy
volunteers. Psychopharmacology 191, 995–1004. doi: 10.1007/s00213-007-
0737-8
Yuan, H., Ding, L., Zhu, M., Zotev, V., Phillips, R., Bodurka, J., et al. (2016).
Reconstructing large-scale brain resting-state networks from high-resolution
EEG: spatial and temporal comparisons with fMRI. Brain Connect. 6, 122–135.
doi: 10.1089/brain.2014.0336
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2018 Serrano, del Castillo, Cortés, Mendes, Arroyo, Andreo, Rocon,
del Valle, Herreros and Romero. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original author(s) and
the copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Neuroscience | www.frontiersin.org 9 October 2018 | Volume 12 | Article 714
